You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead
  1. Aref A Bin Abdulhak1,
  2. Abdur Rahman Khan2,
  3. Imad M Tleyjeh3,4,
  4. Alan P Wimmer1,5
  1. 1Department of Medicine, School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA
  2. 2Department of Medicine, University of Toledo Medical Center, Toledo, Ohio, USA
  3. 3Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA
  4. 4Department of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia
  5. 5Saint Luke's Mid America Heart Institute, University of Missouri Kansas City, Kansas, Missouri, USA
  1. Correspondence to Dr Aref A Bin Abdulhak, Department of Medicine, School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64110, USA; binabdulhaka{at}umkc.edu

https://doi.org/10.1136/heartjnl-2013-304989

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor We read with interest the study by Providencia et al1 which demonstrated that dabigatran had a similar efficacy and safety profile as warfarin in the setting of catheter ablation (CA) of atrial fibrillation (AF). These findings concur with two other meta-analyses on the same topic (including one from our group), which have been …

    View Full Text

    Footnotes

    • Contributors All authors have contributed to the letter.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles